2 型糖尿病伴或不伴心血管疾病患者的止血系统。
The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease.
机构信息
Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
出版信息
Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E57-63. doi: 10.1177/1076029610384112. Epub 2010 Nov 15.
The contribution of the hemostatic system in the development of cardiovascular disease (CVD) in patients with type 2 diabetes is not completely defined. The aim of this study was to elucidate associations of hemostatic factors with the development of CVD in patients with type 2 diabetes. Patients with type 2 diabetes without CVD (n = 113), with CVD (n = 94), and controls without CVD (n = 100) were enrolled in this study. Several hemostatic markers were measured. A disturbed hemostatic balance in patients with type 2 diabetes was observed as illustrated by hypofibrinolysis and increased levels of von Willebrand factor (vWF) and plasminogen-activator inhibitor 1 (PAI-1). Patients with type 2 diabetes with CVD have more thrombin generation compared to patients without CVD. This hemostatic imbalance might contribute to the development of CVD in patients with type 2 diabetes.
止血系统在 2 型糖尿病患者心血管疾病（CVD）发展中的作用尚未完全明确。本研究旨在阐明止血因子与 2 型糖尿病患者 CVD 发展之间的关联。本研究纳入了无 CVD 的 2 型糖尿病患者（n = 113）、有 CVD 的 2 型糖尿病患者（n = 94）和无 CVD 的对照组患者（n = 100）。测量了几种止血标志物。结果显示，2 型糖尿病患者存在纤溶降低、血管性血友病因子（vWF）和纤溶酶原激活物抑制剂 1（PAI-1）水平升高，表明其止血平衡受到干扰。与无 CVD 的患者相比，有 CVD 的 2 型糖尿病患者的凝血酶生成更多。这种止血失衡可能导致 2 型糖尿病患者发生 CVD。
Zotero 插件